In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert reviews the epidemiology, clinical presentation, and differential diagnoses of AD in children, as well as the inflammatory processes driven by type 2 cytokines that lead to AD and its atopic comorbidities

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

This video presentation of the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands features Dr. Stephan Weidinger, Dr. Eric Simpson, and Dr. Marjolein de Bruin-Weller. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating patients with AD early in the disease course, and the emerging real-world data on the use of advanced systemic therapies for patients with AD.

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.